MorphoSys Receives Research Grant to Advance Anti-CD38 Cancer Program MOR202 and Explore Relevant Biomarkers

July 7, 2010 By Leave a Comment

MARTINSRIED, GERMANY and MUNCHEN, GERMANY, Jul 06
(MARKET WIRE) —
MorphoSys AG / MorphoSys Receives Research Grant to Advance Anti-CD38
Cancer Program MOR202 and Explore Relevant Biomarkers processed and
transmitted by Hugin AS. The issuer is solely responsible for the content
of this announcement.

Project is Part of Munich’s Cluster Initiative “m4 – Personalized Medicine
and Targeted Therapies”

MorphoSys AG (FSE: MOR; Prime Standard
Segment, TecDAX) announced today that it has been awarded a grant by the
German Federal Ministry of Education and Research, BMBF. The funding of
approximately EUR 1 million supports MorphoSys in accelerating the
development of its HuCAL-based cancer program MOR202 into clinical
development for the treatment of multiple myeloma. As part of the
program, the Company plans to explore relevant biomarkers for the
anti-CD38 approach in collaboration with Klinikum rechts der Isar, the
university hospital of Munich Technical University. The program is part
of Munich’s biotechnology initiative “m4 – Personalized Medicine and
Targeted Therapies – A New Dimension in Drug Development in the Munich
Region”, which this year received high-tech cluster status in a German
government funding competition.

MOR202 is a fully human, HuCAL antibody directed against CD38, a membrane-
bound glycoprotein that is a promising therapeutic target for the
treatment of multiple myeloma and certain leukemias. In pre-clinical
studies, MOR202 effectively killed cancer cells from primary patient
tumor material and certain hematologic cancer cell lines. Furthermore,
preclinical efficacy was shown by demonstrating inhibition of tumor
growth in SCID-mouse xenograft tumor models. The program is expected to
move into clinical trials in Q1 2011.

“We believe that MOR202 has a very competitive profile and distinct
advantages over similar programs in the industry. As part of the research
program with Klinikum rechts der Isar we plan to explore certain
biomarkers for this new therapeutic approach, thereby further
differentiating our program,” commented Dr. Arndt Schottelius, Chief
Development Officer of MorphoSys AG. “This grant supports the MOR202
program, for which we are on track to file a clinical trial application
in Europe before the end of 2010.”

About MorphoSys:

MorphoSys is an independent biotechnology company that develops novel
antibodies for therapeutic, diagnostic and research applications. The
Company’s HuCAL technology is one of the most powerful methods available
for generating fully human antibodies. By successfully applying this and
other proprietary technologies, MorphoSys has become a leader in the
field of therapeutic antibodies, one of the fastest-growing drug classes
in human health-care. Through its alliances with some of the world’s
leading pharmaceutical companies, MorphoSys has created a pipeline of
more than 60 drug candidates. The Company is expanding its drug pipeline
by adding new partnered programs, and by building a portfolio of
fully-owned therapeutic antibodies. For its proprietary portfolio, the
Company is focused on the areas of oncology and inflammation. Its most
advanced program MOR103, a first-in-class, fully human antibody against
GM- CSF, is currently tested in a Phase Ib/IIa trial in rheumatoid
arthritis patients. Via its business unit AbD Serotec, MorphoSys is
expanding the reach of its technologies in the diagnostics and research
markets. MorphoSys is headquartered in Munich, Germany and listed on the
Frankfurt Stock Exchange under the symbol “MOR”. For further information,
visithttp://www.morphosys.com/

HuCAL(R), HuCAL GOLD(R), HuCAL PLATINUM(R), CysDisplay(R) and RapMAT(R)
are registered trademarks of MorphoSys.

This communication contains
certain forward-looking statements concerning the MorphoSys group of
companies. The forward-looking statements contained herein represent the
judgment of MorphoSys as of the date of this release and involve risks
and uncertainties. Should actual conditions differ from the Company’s
assumptions, actual results and actions may differ from those anticipated.
MorphoSys does not intend to update any of these forward-looking
statements as far as the wording of the relevant press release is
concerned.

For more information, please contact:

MorphoSys AG
Dr. Claudia Gutjahr-Loeser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122

Mario Brkulj
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454

Jessica Kulpi
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332

investors@morphosys.com

[HUG#1429636]

Press Release:

http://hugin.info/130295/R/1429636/376667.pdf

This announcement is
distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other
applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality
of the information contained therein.

All reproduction for further distribution is prohibited.

Source: MorphoSys AG via Thomson Reuters ONE

Copyright 2010, Market Wire, All rights reserved.

Filed Under: International News Tagged With: , , , , , , , , , , , , , , , , , , ,

MorphoSys Receives Research Grant to Advance Anti-CD38 Cancer Program MOR202 and Explore Relevant Biomarkers

July 7, 2010 By Leave a Comment

MARTINSRIED, GERMANY and MUNCHEN, GERMANY, Jul 06
(MARKET WIRE) —
MorphoSys AG / MorphoSys Receives Research Grant to Advance Anti-CD38
Cancer Program MOR202 and Explore Relevant Biomarkers processed and
transmitted by Hugin AS. The issuer is solely responsible for the content
of this announcement.

Project is Part of Munich’s Cluster Initiative “m4 – Personalized Medicine
and Targeted Therapies”

MorphoSys AG (FSE: MOR; Prime Standard
Segment, TecDAX) announced today that it has been awarded a grant by the
German Federal Ministry of Education and Research, BMBF. The funding of
approximately EUR 1 million supports MorphoSys in accelerating the
development of its HuCAL-based cancer program MOR202 into clinical
development for the treatment of multiple myeloma. As part of the
program, the Company plans to explore relevant biomarkers for the
anti-CD38 approach in collaboration with Klinikum rechts der Isar, the
university hospital of Munich Technical University. The program is part
of Munich’s biotechnology initiative “m4 – Personalized Medicine and
Targeted Therapies – A New Dimension in Drug Development in the Munich
Region”, which this year received high-tech cluster status in a German
government funding competition.

MOR202 is a fully human, HuCAL antibody directed against CD38, a membrane-
bound glycoprotein that is a promising therapeutic target for the
treatment of multiple myeloma and certain leukemias. In pre-clinical
studies, MOR202 effectively killed cancer cells from primary patient
tumor material and certain hematologic cancer cell lines. Furthermore,
preclinical efficacy was shown by demonstrating inhibition of tumor
growth in SCID-mouse xenograft tumor models. The program is expected to
move into clinical trials in Q1 2011.

“We believe that MOR202 has a very competitive profile and distinct
advantages over similar programs in the industry. As part of the research
program with Klinikum rechts der Isar we plan to explore certain
biomarkers for this new therapeutic approach, thereby further
differentiating our program,” commented Dr. Arndt Schottelius, Chief
Development Officer of MorphoSys AG. “This grant supports the MOR202
program, for which we are on track to file a clinical trial application
in Europe before the end of 2010.”

About MorphoSys:

MorphoSys is an independent biotechnology company that develops novel
antibodies for therapeutic, diagnostic and research applications. The
Company’s HuCAL technology is one of the most powerful methods available
for generating fully human antibodies. By successfully applying this and
other proprietary technologies, MorphoSys has become a leader in the
field of therapeutic antibodies, one of the fastest-growing drug classes
in human health-care. Through its alliances with some of the world’s
leading pharmaceutical companies, MorphoSys has created a pipeline of
more than 60 drug candidates. The Company is expanding its drug pipeline
by adding new partnered programs, and by building a portfolio of
fully-owned therapeutic antibodies. For its proprietary portfolio, the
Company is focused on the areas of oncology and inflammation. Its most
advanced program MOR103, a first-in-class, fully human antibody against
GM- CSF, is currently tested in a Phase Ib/IIa trial in rheumatoid
arthritis patients. Via its business unit AbD Serotec, MorphoSys is
expanding the reach of its technologies in the diagnostics and research
markets. MorphoSys is headquartered in Munich, Germany and listed on the
Frankfurt Stock Exchange under the symbol “MOR”. For further information,
visithttp://www.morphosys.com/

HuCAL(R), HuCAL GOLD(R), HuCAL PLATINUM(R), CysDisplay(R) and RapMAT(R)
are registered trademarks of MorphoSys.

This communication contains
certain forward-looking statements concerning the MorphoSys group of
companies. The forward-looking statements contained herein represent the
judgment of MorphoSys as of the date of this release and involve risks
and uncertainties. Should actual conditions differ from the Company’s
assumptions, actual results and actions may differ from those anticipated.
MorphoSys does not intend to update any of these forward-looking
statements as far as the wording of the relevant press release is
concerned.

For more information, please contact:

MorphoSys AG
Dr. Claudia Gutjahr-Loeser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122

Mario Brkulj
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454

Jessica Kulpi
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332

investors@morphosys.com

Filed Under: International News Tagged With: , , , , , , , , , , , , , , , , , , ,

MorphoSys AG: MorphoSys Receives Research Grant to Advance Anti-CD38 Cancer Program MOR202 and Explore Relevant Biomarkers

July 7, 2010 By Leave a Comment

MorphoSys AG / MorphoSys Receives Research Grant to Advance Anti-CD38 Cancer Program
MOR202 and Explore Relevant Biomarkers processed and transmitted by Hugin AS. The issuer
is solely responsible for the content of this announcement.

Project is Part of Munich’s Cluster Initiative “m4 – Personalized Medicine and Targeted
Therapies”

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that it has been
awarded a grant by the German Federal Ministry of Education and Research, BMBF. The
funding of approximately EUR 1 million supports MorphoSys in accelerating the
development of its HuCAL-based cancer program MOR202 into clinical development for the
treatment of multiple myeloma. As part of the program, the Company plans to explore
relevant biomarkers for the anti-CD38 approach in collaboration with Klinikum rechts der
Isar, the university hospital of Munich Technical University. The program is part of
Munich’s biotechnology initiative “m4 – Personalized Medicine and Targeted Therapies – A
New Dimension in Drug Development in the Munich Region”, which this year received
high-tech cluster status in a German government funding competition.

MOR202 is a fully human, HuCAL antibody directed against CD38, a membrane-bound
glycoprotein that is a promising therapeutic target for the treatment of multiple
myeloma and certain leukemias. In pre-clinical studies, MOR202 effectively killed cancer
cells from primary patient tumor material and certain hematologic cancer cell lines.
Furthermore, preclinical efficacy was shown by demonstrating inhibition of tumor growth
in SCID-mouse xenograft tumor models. The program is expected to move into clinical
trials in Q1 2011.

“We believe that MOR202 has a very competitive profile and distinct advantages over
similar programs in the industry. As part of the research program with Klinikum rechts
der Isar we plan to explore certain biomarkers for this new therapeutic approach,
thereby further differentiating our program,” commented Dr. Arndt Schottelius, Chief
Development Officer of MorphoSys AG. “This grant supports the MOR202 program, for which
we are on track to file a clinical trial application in Europe before the end of 2010.”

About MorphoSys:

MorphoSys is an independent biotechnology company that develops novel antibodies for
therapeutic, diagnostic and research applications. The Company’s HuCAL technology is one
of the most powerful methods available for generating fully human antibodies. By
successfully applying this and other proprietary technologies, MorphoSys has become a
leader in the field of therapeutic antibodies, one of the fastest-growing drug classes
in human health-care. Through its alliances with some of the world’s leading
pharmaceutical companies, MorphoSys has created a pipeline of more than 60 drug
candidates. The Company is expanding its drug pipeline by adding new partnered programs,
and by building a portfolio of fully-owned therapeutic antibodies. For its proprietary
portfolio, the Company is focused on the areas of oncology and inflammation. Its most
advanced program MOR103, a first-in-class, fully human antibody against GM-CSF, is
currently tested in a Phase Ib/IIa trial in rheumatoid arthritis patients. Via its
business unit AbD Serotec, MorphoSys is expanding the reach of its technologies in the
diagnostics and research markets. MorphoSys is headquartered in Munich, Germany and
listed on the Frankfurt Stock Exchange under the symbol “MOR”. For further information,
visit http://www.morphosys.com/ http://www.morphosys.com/

HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay® and RapMAT® are registered trademarks
of MorphoSys.

This communication contains certain forward-looking statements concerning the MorphoSys
group of companies. The forward-looking statements contained herein represent the
judgment of MorphoSys as of the date of this release and involve risks and
uncertainties. Should actual conditions differ from the Company’s assumptions, actual
results and actions may differ from those anticipated. MorphoSys does not intend to
update any of these forward-looking statements as far as the wording of the relevant
press release is concerned.

For more information, please contact:

MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122

Mario Brkulj
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454

Jessica Kulpi
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332

investors@morphosys.com mailto:investors@morphosys.com

HUG#1429636

Press Release http://hugin.info/130295/R/1429636/376667.pdf

— End of Message —

MorphoSys AG
Lena-Christ-Str. 48 Martinsried / München Germany

WKN: 663200;ISIN: DE0006632003;Index:TecDAX,Prime All Share,CDAX,TECH All
Share,HDAX,MIDCAP;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;

Filed Under: International News Tagged With: , , , , , , , , , , , , , , , , , , ,

Bombardier Aerospace: Bombardier Receives CofA for First Global 5000 Jet to be Operated by the German Federal Ministry of Defense

June 9, 2010 By Leave a Comment

BERLIN, GERMANY–(Marketwire – June 8, 2010) – Today, Bombardier Aerospace announced
that Transport Canada has issued the Certificate of Airworthiness (CofA) for the first
Global 5000 jet to be operated by the German Federal Ministry of Defense (FMOD).

In December 2007, the German Federal Office of Defense Technology and Procurement (BWB)
selected the Global 5000 jet as a key component of their plan for the modernization of
the FMOD’s Special Mission Wing. Four Global 5000 jets, to be completed at Bombardier’s
Global Completion Centre in Montreal, will be operated by the German FMOD’s Special
Mission Wing for VIP transport and Medical Evacuation (MedEvac) flights.

“This is a significant step toward the completion of this fleet modernization program,”
said Derek Gilmour, Vice President, Sales, Marketing and Administration, Bombardier
Specialized and Amphibious Aircraft. “The Global 5000 jet is the aircraft best suited to
meet the BWB tender 12-seat jet requirement, which includes intercontinental range and
the ability to reconfigure the interior for MedEvac capabilities, with an option to
carry an intensive care patient transport unit when required.”

“This Certificate of Airworthiness marks an important milestone for the German Federal
Ministry of Defense,” said Stefan Rauscher, Project Manager, BWB. “The speed, comfort,
and versatility of the Global 5000 aircraft are a perfect fit with our needs, and we are
looking forward to beginning operations with our new jets.”

Lufthansa Technik AG of Hamburg, Germany, was selected as the prime contractor for the
overall agreement, which also included the purchase of two Airbus A319(i) corporate
jetliners. The six new aircraft will replace the FMOD’s existing fleet of Challenger 601
aircraft. German Operating Aircraft Leasing GmbH & Co. KG (GOAL), a joint venture of
Deutsche Lufthansa AG and KGAL GmbH & Co. KG, is acting as a subcontractor for Lufthansa
Technik AG with respect to the acquisition of the four Global 5000 aircraft. GOAL is
Germany’s largest operating lessor, and its current portfolio consists of 56 owned and
managed aircraft.

Fastest time ever recorded for a civil flight between Berlin and Washington, DC

A Global 5000 jet set a new speed record on October 21, 2007, flying 3,652 nautical
miles (6,765 km) non-stop from Berlin to Washington, DC, in just eight hours, 17
minutes. This fourth National Aeronautic Association-sanctioned world record performance
for the Global 5000 jet represents the fastest time ever recorded for a civil flight
between Berlin and Washington, DC.

The benefit of the aircraft’s category-leading speed is most evident on non-stop
intercontinental flights. Compared to other jets in its class, the Global 5000 jet trims
up to a full hour from long distance routes, such as Moscow-New York in nine hours, 29
minutes, Johannesburg-Geneva in 10 hours, Jeddah-Jakarta in nine hours, 53 minutes and
Sao Paulo-Madrid in nine hours, 20 minutes(ii).

With a best-in-class balanced field length at takeoff of 5,000 feet (1,524 m) (Sea
Level, MTOW, ISA), and a landing distance (MLW, ISA, SL) of 2,670 feet (814 m), Global
5000 aircraft operators are able to fly in and out of challenging airfields that are
closer to their areas of business.

About Bombardier

A world-leading manufacturer of innovative transportation solutions, from commercial
aircraft and business jets to rail transportation equipment, systems and services,
Bombardier Inc. is a global corporation headquartered in Canada. Its revenues for the
fiscal year ended Jan. 31, 2010, were $19.4 billion, and its shares are traded on the
Toronto Stock Exchange (BBD). Bombardier is listed as an index component to the Dow
Jones Sustainability World and North America indexes. News and information are available
at www.bombardier.com http://www.bombardier.com .

Note to editors

Statements about performance and design as stated in this document are solely based on
projections and forecasts, and are subject to change without notice.

Bombardier, Challenger 601, Global and Global 5000 are either registered or unregistered
trademarks of Bombardier Inc. or its subsidiaries.

(i) Airbus and A319 are registered trademarks of Airbus S.A.S.

(ii) Under certain operating conditions.

Contacts:
Bombardier Aerospace
Marc Duchesne
1-514-855-7989
www.bombardier.com http://www.bombardier.com

HUG#1422283

Filed Under: International News Tagged With: , , , , , , , , , , , , , , , , , , ,

Bombardier Receives CofA for First Global 5000 Jet to be Operated by the German Federal Ministry of Defense

June 9, 2010 By Leave a Comment

BERLIN, GERMANY, Jun 08 (MARKET WIRE) —
Today, Bombardier Aerospace announced that Transport Canada has issued
the Certificate of Airworthiness (CofA) for the first Global 5000 jet to
be operated by the German Federal Ministry of Defense (FMOD).

In December 2007, the German Federal Office of Defense Technology and
Procurement (BWB) selected the Global 5000 jet as a key component of
their plan for the modernization of the FMOD’s Special Mission Wing. Four
Global 5000 jets, to be completed at Bombardier’s Global Completion
Centre in Montreal, will be operated by the German FMOD’s Special Mission
Wing for VIP transport and Medical Evacuation (MedEvac) flights.

“This is a significant step toward the completion of this fleet
modernization program,” said Derek Gilmour, Vice President, Sales,
Marketing and Administration, Bombardier Specialized and Amphibious
Aircraft. “The Global 5000 jet is the aircraft best suited to meet the
BWB tender 12-seat jet requirement, which includes intercontinental range
and the ability to reconfigure the interior for MedEvac capabilities,
with an option to carry an intensive care patient transport unit when
required.”

“This Certificate of Airworthiness marks an important milestone for the
German Federal Ministry of Defense,” said Stefan Rauscher, Project
Manager, BWB. “The speed, comfort, and versatility of the Global 5000
aircraft are a perfect fit with our needs, and we are looking forward to
beginning operations with our new jets.”

Lufthansa Technik AG of Hamburg, Germany, was selected as the prime
contractor for the overall agreement, which also included the purchase of
two Airbus A319(i) corporate jetliners. The six new aircraft will replace
the FMOD’s existing fleet of Challenger 601 aircraft. German Operating
Aircraft Leasing GmbH & Co. KG (GOAL), a joint venture of Deutsche
Lufthansa AG and KGAL GmbH & Co. KG, is acting as a subcontractor for
Lufthansa Technik AG with respect to the acquisition of the four Global
5000 aircraft. GOAL is Germany’s largest operating lessor, and its
current portfolio consists of 56 owned and managed aircraft.

Fastest time ever recorded for a civil flight between Berlin and
Washington, DC

A Global 5000 jet set a new speed record on October 21, 2007, flying
3,652 nautical miles (6,765 km) non-stop from Berlin to Washington, DC,
in just eight hours, 17 minutes. This fourth National Aeronautic
Association-sanctioned world record performance for the Global 5000 jet
represents the fastest time ever recorded for a civil flight between
Berlin and Washington, DC.

The benefit of the aircraft’s category-leading speed is most evident on
non-stop intercontinental flights. Compared to other jets in its class,
the Global 5000 jet trims up to a full hour from long distance routes,
such as Moscow-New York in nine hours, 29 minutes, Johannesburg-Geneva in
10 hours, Jeddah-Jakarta in nine hours, 53 minutes and Sao Paulo-Madrid
in nine hours, 20 minutes(ii).

With a best-in-class balanced field length at takeoff of 5,000 feet
(1,524 m) (Sea Level, MTOW, ISA), and a landing distance (MLW, ISA, SL)
of 2,670 feet (814 m), Global 5000 aircraft operators are able to fly in
and out of challenging airfields that are closer to their areas of
business.

About Bombardier

A world-leading manufacturer of innovative transportation solutions, from
commercial aircraft and business jets to rail transportation equipment,
systems and services, Bombardier Inc. is a global corporation
headquartered in Canada. Its revenues for the fiscal year ended Jan. 31,
2010, were $19.4 billion, and its shares are traded on the Toronto Stock
Exchange (BBD). Bombardier is listed as an index component to the Dow
Jones Sustainability World and North America indexes. News and
information are available at www.bombardier.com.

Note to editors

Statements about performance and design as stated in this document are
solely based on projections and forecasts, and are subject to change
without notice.

Bombardier, Challenger 601, Global and Global 5000 are either registered
or unregistered trademarks of Bombardier Inc. or its subsidiaries.

(i) Airbus and A319 are registered trademarks of Airbus S.A.S.

(ii) Under certain operating conditions.

Contacts:
Bombardier Aerospace
Marc Duchesne
1-514-855-7989
www.bombardier.com

Copyright 2010, Market Wire, All rights reserved.

Filed Under: International News Tagged With: , , , , , , , , , , , , , , , , , , ,